{"createdAt":"8/2/2020, 2:46:02 PM","timestamp":1596393962640,"Company ID number":"828","DMX_ISSUER_NAME":"LBX Pharmacy Chain Joint Stock Company","DMX_ISSUER_ID":"IID000000002729154","Country of Classification":"CHINA","name":"LBX Pharmacy Chain JSC","code":"603883","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"老百姓大药房连锁股份有限公司_谢子龙","group":"board","name":"谢子龙","title":"董事长,董事","isMale":true,"age":"54","degree":"硕士","salary":"216.0万","stockAmount":"-","description":"谢子龙先生,中国国籍,EMBA在读,公司创始人。现任老百姓大药房连锁股份有限公司第三届董事会董事长、中国医药商业协会副会长、湖南省摄影家协会主席、湖南省药品流通行业协会会长。老百姓大药房连锁股份有限公司第一、二届董事会董事长、董事会执行委员会委员、董事会战略委员会主任委员,第十一届、十二届全国人大代表、湖南省工商业联合会副主席。曾先后获得2015年全国劳动模范荣誉称号、全国道德模范提名奖、中国好人等荣誉。现拟任公司总裁职务。","lastUpdated":"2018-03-01"},{"id":"老百姓大药房连锁股份有限公司_黄玕","group":"board","name":"黄玕","title":"董事","isMale":true,"age":"43","degree":"本科","salary":"8.330万","stockAmount":"-","description":"黄玕先生,43岁,中国国籍,吉林大学法学学士。曾先后就任海航集团有限公司执行总裁、海航实业集团有限公司执行董事长、海航物流集团有限公司董事长兼CEO以及海航集团董事局董事等职务,现任北京信源健和科技有限责任公司总裁。","lastUpdated":"2019-03-28"},{"id":"老百姓大药房连锁股份有限公司_武滨","group":"board","name":"武滨","title":"董事","isMale":true,"age":"60","degree":"硕士","salary":"10.00万","stockAmount":"800","description":"武滨,1960年出生,研究生,高级咨询师,执业药师。曾经历任山西省医药公司企业管理科副科长,山西省医药管理局商业处副处长,山西省药材公司副经理,山西省医药集团有限公司经济运行部部长、总经理助理;现任中国医药商业协会副会长。","lastUpdated":"2018-02-28"},{"id":"老百姓大药房连锁股份有限公司_吕明方","group":"board","name":"吕明方","title":"董事","isMale":true,"age":"63","degree":"硕士","salary":"0.00","stockAmount":"-","description":"吕明方,1957年出生,男,中国国籍,无境外永久居留权,复旦大学经济学学士、经济学硕士,中国香港中文大学专业会计学硕士。曾任中国香港上海实业集团执行董事、副总裁,上海医药集团执行董事、董事长,现任方源资本(亚洲)有限公司合伙人、董事总经理。吕先生于一九九七年四月加入，担任联华超市股份有限公司非执行董事。","lastUpdated":"2020-01-16"},{"id":"老百姓大药房连锁股份有限公司_郑嘉齐","group":"board","name":"郑嘉齐","title":"董事","isMale":true,"age":"37","degree":"硕士","salary":"0.00","stockAmount":"-","description":"郑嘉齐,1983年出生,男,中国国籍,有境外永久居留权,英国曼彻斯特大学经济学本科学士,英国兰卡斯特大学金融学硕士研究生。曾任中国国际金融有限公司经理,现任春华资本集团董事总经理。","lastUpdated":"2020-01-16"},{"id":"老百姓大药房连锁股份有限公司_李炜","group":"board","name":"李炜","title":"董事","isMale":true,"age":"38","degree":"本科","salary":"0.00","stockAmount":"-","description":"李炜,1982年出生,男,中国国籍,无境外永久居留权,湖南大学新闻传播专业本科学士。曾任湖南经济电视台团委副书记、制片人;湖南广播电视台台办副主任;芒果传媒有限公司行政总监,现任天津银河酷娱文化传媒有限公司CEO。","lastUpdated":"2020-01-16"},{"id":"老百姓大药房连锁股份有限公司_黄伟德","group":"board","name":"黄伟德","title":"独立董事","isMale":true,"age":"49","degree":"本科","salary":"10.00万","stockAmount":"-","description":"黄伟德先生,1971年5月出生,中国香港会计师公会会员,现任中远海运能源运输股份有限公司独立非执行董事、审计委员会主任委员和提名委员会委员,利邦控股有限公司(股票代码:00891.HK)、万宝盛华大中华有限公司(股票代码:02180.HK)、思考乐教育集团(股票代码:01769.HK)、滔搏国际控股有限公司(股票代码:06110.HK)、煜盛文化集团(股票代码:01859.HK)、老百姓大药房连锁股份有限公司(股票代码:603883.SS)以及青岛海尔生物医疗股份有限公司(股票代码:688139.SS)的独立非执行董事。黄先生于1992年获得美国加州大学洛杉矶分校的经济学士学位,曾为普华永道会计师事务所和毕马威会计师事务所的合伙人,在会计、审计及并购工作方面具约30年经验。于2020年6月19日获委任为新时代能源有限公司独立非执行董事。","lastUpdated":"2018-02-28"},{"id":"老百姓大药房连锁股份有限公司_单喆慜","group":"board","name":"单喆慜","title":"独立董事","isMale":false,"age":"48","degree":"博士","salary":"10.00万","stockAmount":"-","description":"单喆慜女士:中国籍,无境外永久居留权,1972年出生,上海财经大学管理学博士,中国注册会计师。曾任职于上海财经大学、申银万国证券股份有限公司。现任上海国家会计学院教授,同时担任光正集团股份有限公司独立董事、上海兰生股份有限公司独立董事、老百姓大药房连锁股份有限公司独立董事、润中国际控股有限公司独立非执行董事,以及福建华通银行股份有限公司独立董事、城云国际有限公司独立董事等职务。2016年5月至今任奥瑞金科技股份有限公司独立董事。","lastUpdated":"2018-02-28"},{"id":"老百姓大药房连锁股份有限公司_周京","group":"board","name":"周京","title":"独立董事","isMale":false,"age":"56","degree":"博士","salary":"10.00万","stockAmount":"-","description":"周京女士,1964年出生,中国国籍,工商管理博士,主任教授。2003年至今任职于美国莱斯大学,历任商业领域副教授、教授和主任教授职务。曾荣获“中国’千人计划’(管理类)专家”、清华大学特聘“杰出访问讲席教授”等称号。","lastUpdated":"2018-02-28"},{"id":"老百姓大药房连锁股份有限公司_饶浩","group":"supervisoryCommittee","name":"饶浩","title":"监事","isMale":true,"age":"42","degree":"本科","salary":"20.00万","stockAmount":"-","description":"饶浩先生,1978年出生,中国国籍,本科学历。饶浩先生于2008年加入老百姓大药房连锁股份有限公司,曾任职于公司之子公司河南公司财务部长、广东公司财务部长及公司计划分析部长,现任老百姓大药房连锁股份有限公司内控部长。","lastUpdated":"2018-02-28"},{"id":"老百姓大药房连锁股份有限公司_周勇","group":"supervisoryCommittee","name":"周勇","title":"监事","isMale":true,"age":"48","degree":"硕士","salary":"54.00万","stockAmount":"-","description":"周勇,1972年出生,男,中国国籍,无境外永久居留权,MBA硕士研究生。曾任宁波方太集团部长、欧普照明股份有限公司人力资源与行政总监,现任老百姓大药房连锁股份有限公司人力资源与培训总监。","lastUpdated":"2020-01-16"},{"id":"老百姓大药房连锁股份有限公司_谭坚","group":"supervisoryCommittee","name":"谭坚","title":"职工监事","isMale":true,"age":"43","degree":"本科","salary":"31.00万","stockAmount":"-","description":"谭坚先生,1977年出生,中国国籍,学士学历。2000年获得湖南中医学院中医临床医学学士学位。曾任职于爱尔眼科,从事医疗用品的采购管理工作。谭坚先生于2008年加入老百姓大药房连锁股份有限公司,现任督察审计中心总监。","lastUpdated":"2018-02-03"},{"id":"老百姓大药房连锁股份有限公司_冯诗倪","group":"manager","name":"冯诗倪","title":"董事会秘书","isMale":false,"age":"35","degree":"硕士","salary":"22.00万","stockAmount":"2.112万","description":"冯诗倪女士,35岁,中国国籍,中南大学工商管理硕士,先后在三一重工股份有限公司担任重工总裁办综合服务经理、宣传文化部媒体主管、证券部投资者关系经理,爱尔眼科医院集团股份有限公司担任董秘办副主任等职务。","lastUpdated":"2019-08-10"},{"id":"老百姓大药房连锁股份有限公司_朱景炀","group":"manager","name":"朱景炀","title":"副总裁,财务负责人","isMale":true,"age":"45","degree":"本科","salary":"72.00万","stockAmount":"2.36万","description":"朱景炀先生,中国国籍,本科学历,注册会计师、注册税务师。曾就职于广东步步高电子工业有限公司、德勤会计师事务所、光普电子(苏州)有限公司和亚洲铝业(中国)有限公司等公司。现任老百姓大药房连锁股份有限公司财务负责人,拟任公司副总裁,主管财务方面。","lastUpdated":"2018-07-19"},{"id":"老百姓大药房连锁股份有限公司_胡健辉","group":"manager","name":"胡健辉","title":"副总裁","isMale":true,"age":"45","degree":"硕士","salary":"119.0万","stockAmount":"2.62万","description":"胡健辉先生,1975年出生,中国国籍,硕士学历。拥有超过20年专业的市场研究数据处理经验,负责超过900个市场研究项目的数据处理及问卷设计指导,曾自主原创独立研发出国内首个市场研究专业的逻辑引擎,掌握CAPI、CAWI、CATI、Online等多种市场研究的先进技术,擅长对研究项目的数据处理、统计分析。先后就职于Added-Value艾德惠研市场研究公司、北京捷孚凯市场调查有限公司、广州清雪市场研究有限公司、G.S.S.Y.MarketResearchDataProcessCenter(China)等公司。现任老百姓大药房连锁股份有限公司副总裁。","lastUpdated":"2018-03-01"},{"id":"老百姓大药房连锁股份有限公司_张林安","group":"manager","name":"张林安","title":"副总裁","isMale":true,"age":"56","degree":"硕士","salary":"91.00万","stockAmount":"2.36万","description":"张林安先生,1964年出生,中国国籍,EMBA在读,经济师,会计师。先后就职于湖南中意集团股份有限公司、湖南投资集团股份有限公司、湖南鸿仪投资集团有限公司、威胜集团有限公司、湖南成功控股集团有限公司、湖南天宜创业投资有限公司、湖南省明园蜂业有限公司等企业,曾任湖南老百姓大药房连锁有限公司财务总监、投资总监及老百姓大药房连锁股份有限公司财务负责人职务。现任老百姓大药房连锁股份有限公司副总裁。","lastUpdated":"2018-03-01"},{"id":"老百姓大药房连锁股份有限公司_杨芳芳","group":"manager","name":"杨芳芳","title":"副总裁","isMale":false,"age":"39","degree":"本科","salary":"111.0万","stockAmount":"2.36万","description":"杨芳芳女士,中国国籍,本科学历,国家执业中药师、国家二级营养师。于2002年12月加入老百姓大药房连锁有限公司至今16年,先后担任超级旗舰店店长、运营部长、营运总监、广西公司总经理、湘赣大区总经理等岗位;擅长团队构建、商品营销、目标管理、市场拓展等。现拟任公司副总裁职务,主管营运方面。","lastUpdated":"2018-07-19"},{"id":"老百姓大药房连锁股份有限公司_王琴","group":"manager","name":"王琴","title":"副总裁","isMale":false,"age":"48","degree":"硕士","salary":"88.00万","stockAmount":"2.62万","description":"王琴女士,中国国籍,硕士学历,职业药师、营养师。善长于采购战略规划;集团战略合作谈判管理;商品分析、商品力提升,采购成本控制,企业规模资源优势获取的能力;拥有医药生产企业、批发企业、零售企业的产业链营销经验,曾就职于湖南制药有限公司、长沙双鹤医药有限责任公司;老百姓大药房连锁股份有限公司陕西公司,现拟任公司釆购副总裁,主管采购方面。","lastUpdated":"2018-07-19"}],"companyName":"老百姓大药房连锁股份有限公司","province":"湖南省","englishName":"","industry":"医药生物 — 医药商业Ⅱ","website":"www.lbxdrugs.com","mainBusiness":"药品及健康相关商品的销售","productsName":["中西成药","中药","非药品"],"actualController":"谢子龙、陈秀兰","actualControllerSharePercentage":"22.76、11.76%","registeredCapital":"2.92亿元","employeeAmount":"23109","phone":"86-0731-84035189","location":"湖南省长沙市开福区青竹湖路808号","chineseDescription":"老百姓大药房连锁股份有限公司是一家由单体民营药店发展起来的中外合资大型药品零售连锁企业。\n　　2019年7月，老百姓大药房获得《2018~2019年度中国连锁药店8维·品牌冠军》、《2018~2019年度中国连锁药店综合实力百强企业》、《2018~2019年度中国连锁药店直营力百强企业》等荣誉；2019年8月，根据中康资讯·中国药品零售发展研究中心评选，老百姓大药房获得“中国药品零售企业综合竞争力”第一名及“中国药品零售企业综合竞争力7力冠军”中“品牌力冠军”等荣誉。","foundedDate":"2005-12-01","goPublicDate":"2015-04-23","companyHistory":"老百姓大药房连锁股份有限公司(以下简称“本公司”)，注册地为中华人民共和国湖南省长沙市，总部地址为中华人民共和国湖南省长沙市。\n　　本公司于2015年4月向境内投资者公开发行人民币普通股6,700万股，发行后总股本为26,700万股，每股发行价为16.41元，募集资金总额为1,099,470,000元，扣除发行费用89,442,310元后，募集资金净额为1,010,027,690元。本公司于2015年4月23日在上海证券交易所挂牌上市交易。于2016年6月30日，本公司的总股本为267,000,000元，每股面值1元。\n　　于2017年11月，本公司采用非公开发售方式向特定投资者发行人民币普通股17,945,266股，每股发行价为44.58元，募集资金总额为799,999,958元，扣除发行费用10,263,344元后，募集资金净额为789,736,614元。\n　　根据《老百姓大药房连锁股份有限公司2019年限制性股票激励计划》，公司向207名激励对象授予1,611,099股限制性股票，中国证券登记结算有限责任公司上海分公司已于2019年4月24日完成对公司激励计划首次授予权益的审核与登记。截至2019年6月30日公司总股本由284,945,266股增加到286,556,365股，面值为1元。\n　　于2019年12月31日，本公司的总股本为286,687,533元，每股面值1元。收起▲","shareholders":[{"organizationId":"T000292419","holderName":"老百姓医药集团有限公司","totalShare":"9918.08万","sharePercentage":"34.60%"},{"organizationId":"","holderName":"泽星投资有限公司","totalShare":"7101.14万","sharePercentage":"24.77%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"910.20万","sharePercentage":"3.17%"},{"organizationId":"","holderName":"陈秀兰","totalShare":"573.36万","sharePercentage":"2.00%"},{"organizationId":"","holderName":"交通银行股份有限公司-国泰金鹰增长灵活配置混合型证券投资基金","totalShare":"535.88万","sharePercentage":"1.87%"},{"organizationId":"","holderName":"石展","totalShare":"530.98万","sharePercentage":"1.85%"},{"organizationId":"","holderName":"兴业银行股份有限公司-兴全趋势投资混合型证券投资基金","totalShare":"504.23万","sharePercentage":"1.76%"},{"organizationId":"","holderName":"兴业银行股份有限公司-兴全新视野灵活配置定期开放混合型发起式证券投资基金","totalShare":"471.00万","sharePercentage":"1.64%"},{"organizationId":"","holderName":"国泰基金管理有限公司-社保基金1102组合","totalShare":"304.13万","sharePercentage":"1.06%"},{"organizationId":"","holderName":"中国工商银行股份有限公司-中海医疗保健主题股票型证券投资基金","totalShare":"276.00万","sharePercentage":"0.96%"}],"englishDescription":"","englishIndustry":"","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"13,385.01","Cash payments":"(8,856.44)","Cash taxes paid":"(572.23)","Changes in working capital":"(2,923.79)","Cash from operating activities":"1,032.54","Capital expenditures":"(426.40)","Other investing cash flow items, total":"(411.15)","Cash from investing activities":"(837.55)","Financing cash flow items":"(24.80)","Total cash dividends paid":"(230.74)","Issuance (retirement) of debt, net":"159.78","Cash from financing activities":"(95.77)","Net change in cash":"99.22"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"104.00","52 Week High":"116.13","52 Week Low":"60.43","Pricing date":"","10 Day Average Trading Volume":"3.55","Market Capitalization":"30,368.04","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"78.16","Beta":"0.85","1 Day Price Change":"-0.82","13 Week Price Return (Daily)":"36.68","26 Week Price Return (Daily)":"41.50","5 Day Price Return (Daily)":"-0.43","52 Week Price Return (Daily)":"56.32","Year To Date Price Return (Daily)":"62.30","Month to Date Price Return (Daily)":"3.96","Price Relative to S&P500 (4 Week)":"5.61","Price Relative to S&P500 (13 Week)":"18.10","Price Relative to S&P500 (26 Week)":"27.24","Price Relative to S&P500 (52 Week)":"37.37","Price Relative to S&P500 (YTD)":"49.55"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.76","EPS excl. Extra Items (TTM)":"1.89","EPS Normalized (Annual)":"1.76","Revenue per Share (Annual)":"40.35","Revenue per Share (TTM)":"42.37","Book Value (Per Share Annual)":"12.16","Book Value (Per Share Quarterly)":"12.87","Tangible Book Value (Per Share Annual)":"2.54","Tangible Book Value (Per Share Quarterly)":"2.70","Cash Per Share (Per Share Annual)":"3.04","Cash Per Share (Per Share Quarterly)":"4.95","Cash Flow (Per Share Annual)":"2.46","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.42","Dividends (Per Share TTM)":"0.42","EBITD (Per Share TTM)":"3.11","EPS Basic excl. Extra Items (Annual)":"1.78","EPS Basic excl. Extra Items (TTM)":"1.92","EPS incl. Extra Items (Annual)":"1.76","EPS incl. Extra Items (TTM)":"1.89","Free Cash Flow (Per Share TTM)":"1.36","Dividend (Per Share 5Y)":"0.50"},"Valuation":{"P/E excl. Extra Items (Annual)":"59.09","P/E excl. Extra Items (TTM)":"54.98","P/E Normalized (Annual)":"58.97","Price to sales (Annual)":"2.60","Price to sales (TTM)":"2.49","Price to Tangible Book (Annual)":"41.72","Price to Tangible Book (Quarterly)":"39.29","Price to Free Cash Flow (Per Share Annual)":"80.90","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"77.68","Price to Book (Annual)":"8.55","Price to Book (Quarterly)":"8.08","P/E Basic excl. Extra Items (TTM)":"40.59","P/E excl. Extra Items High (TTM)":"69.42","P/E excl. Extra Items Low (TTM)":"30.92","P/E incl. Extra Items (TTM)":"54.98","Net Debt (Interim)":"2,645.13","Net Debt (Annual)":"2,956.63","Dividend Yield (5Y)":"0.86","Dividend Yield":"0.48","Current Dividend Yield (TTM)":"0.40"},"Financial Strength":{"Free Cash Flow (Annual)":"375.40","Current Ratio (Annual)":"0.95","Net Interest coverage (Annual)":"18.29","Long Term Debt/Equity (Annual)":"18.60","Payout Ratio (Annual)":"23.66","Quick Ratio (Annual)":"0.58","Total Debt/Total Equity (Annual)":"109.79","Current EV/Free Cash Flow (Annual)":"637.12","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"0.97","Long Term Debt/Equity (Quarterly)":"17.68","Quick Ratio (Quarterly)":"0.58","Total Debt/Total Equity (Quarterly)":"110.19","Free Cash Flow (TTM)":"390.95","Net Interest Coverage (TTM)":"13.61","Payout Ratio (TTM)":"22.07"},"Margins":{"Gross Margin (Annual)":"33.54","Gross Margin (TTM)":"32.94","Net Profit Margin % (Annual)":"5.27","Net Profit Margin (TTM)":"5.43","Operating Margin (Annual)":"6.56","Operating Margin (TTM)":"6.80","Pretax Margin (TTM)":"6.83","Pretax Margin (Annual)":"6.61","Operating Margin (5Y)":"6.71","Pretax Margin (5Y)":"6.82","Free Operating Cash Flow/Revenue (5Y)":"0.66","Free Operating Cash Flow/Revenue (TTM)":"3.20","Gross Margin (5Y)":"35.05","Net Profit Margin (5Y)":"5.43"},"Management Effectiveness":{"Return on Assets (Annual)":"6.68","Return on Equity (TTM)":"6.72","Return on Average Equity (Annual)":"15.57","Return on Average equity (TTM)":"15.72","Return on Investment (Annual)":"16.61","Return on Investment (TTM)":"16.92","Return on Average Assets (5Y)":"7.09","Return on Average Equity (5Y)":"15.09","Return on Investment (5Y)":"14.61","Asset Turnover (Annual)":"1.27","Asset Turnover (TTM)":"1.24","Inventory Turnover (Annual)":"4.19","Inventory Turnover (TTM)":"3.92","Net Income/Employee (Annual)":"28,653.19","Net Income/Employee (TTM)":"28,686.23","Receivables Turnover (Annual)":"11.59","Receivables Turnover (TTM)":"11.61","Revenue/Employee (Annual)":"543,408.50","Revenue/Employee (TTM)":"528,707.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"20.34","Revenue Growth Rate (5Y)":"24.22","EPS Growth (Quarterly YoY)":"22.22","EPS Growth (TTM YoY)":"16.41","EPS Growth Rate (5Y)":"11.71","Dividend Growth Rate (3Y)":"11.87","Revenue Growth (TTM YoY)":"22.33","Revenue Growth (Per Share 5Y)":"15.40","Revenue Growth Rate (3Y)":"24.15","EPS Growth Rate (3Y)":"16.54","Book Value Growth Rate (Per Share 5Y)":"20.24","Tangible Book Value Total Equity CAGR (5Y)":"9.09","Capital Spending growth rate 5 year":"29.38","EBITDA CAGR (5Y)":"20.88","EBITDA Interim CAGR (5Y)":"21.48","Free Operating Cash Flow CAGR (5Y)":"44.04","Total Debt CAGR (5Y)":"41.70","Net Profit Margin Growth Rate (5Y)":"-2.67"},"Income Statement":{"Revenue (Annual)":"11,663.18","Revenue (TTM)":"12,217.89","EBITD (Annual)":"905.80","EBITD (TTM)":"897.84","Earnings Before Taxes (Annual)":"770.38","Earnings Before Taxes (TTM)":"834.14","Net Income to Common (Annual)":"508.71","Net Income to Common (TTM)":"545.39","Earnings Before Taxes Normalized (Annual)":"771.73","Net Income Available to Common Normalized (Annual)":"509.78","Diluted Normalized EPS excl. Extra Items (TTM)":"1.89"}}}